Introduction
Obesity, defined as body mass index (BMI) 430 kg/ m 2 , is a common disorder that affects over one-third of adult Americans.
1 It is associated with numerous comorbid conditions, such as hypertension (HTN), diabetes, dyslipidaemia, atherosclerosis, focal segmental glomerulosclerosis (FSGS), glomerulomegaly and chronic renal failure (CRF). [2] [3] [4] [5] Up to 50% of obese individuals have concomitant HTN. 3, 6 There is cumulating evidence suggesting that obesity per se, is the cause of HTN in obese subjects. 3, [7] [8] [9] Obesity-associated HTN has a complex, multifactorial mechanism, including activation of the sympathetic nervous system (SNS) and the reninangiotensin systems (RAS), insulin resistance, excess renal sodium reabsorption, leptin-resistance and natriuretic peptides (NPs) downregulation. [7] [8] [9] Pressure natriuresis normally seen with increased blood pressure (BP) is blunted in obesity. 9, 10 Obesity-HTN causes haemodynamic and structural adaptations in the renal and cardiovascular systems. In the kidney, it causes hyperperfusion, hyperfiltration, proteinuria, glomerulosclerosis and CRF. In the heart, it causes concentric-eccentric left ventricular hypertrophy (LVH), development of congestive heart failure (CHF), arrhythmia and cardiac sudden death.
Detection, Evaluation, and Treatment of High Blood Pressure, do not provide specific recommendations for the pharmacological management of obesity-HTN, 11 because the data from clinical studies in obese population are scarce. In this review, we will summarize the available data, discuss the theoretical reasons and clinical approaches for the pharmacological and nonpharmacological treatments of obesity-HTN. We will also emphasize the specific considerations needed for the prevention of renal and cardiovascular damage in these subjects.
Weight reduction as a first-line therapy
Weight reduction may be achieved by behavior modification, diet control, exercise, or use of antiobesity medications. As a result of the side effect of HTN, noradrenergic appetite-suppressant agents (benzphetamine, phendimetrazine, phentermine and diethylpropion) should not be used in hypertensive obese patients. Sibutramine, a mixed noradrenergic and serotonergic agent, can also increase BP. It should be avoided in obese subjects with uncontrolled HTN. The reductions in BP in those who lose weight with sibutramine are usually less than the reductions in BP seen with similar weight loss obtained by other treatments. 12 Evidence shows that weight reduction is an effective treatment for reducing BP in obesity-HTN. 13, 14 In a study in which salt was not restricted, we showed that 75% of obese hypertensive patients returned to normal BP following a weight loss of 10 kg, which indicated that weight loss independent of salt restriction was an effective way in controlling BP. 13 Additionally, significant reduction of BP can be observed even if the patient's weight loss is less than needed to reach their ideal weight.
Weight loss can frequently obviate the need of antihypertensive drugs. 13, 14 In the Dietary Intervention Study in Hypertension (DISH), obese hypertensives were separated into three groups: weight reduction, dietary sodium restriction, or no intervention as controls. The average weight loss in the weight reduction group was 4.5 kg after 1 year, and 60% of them remained normotensive without any antihypertensive medication. When daily sodium intake was reduced to 40 meq, 46% of them maintained normotensive. Only 30% of the control group remained normotensive without medication. The beneficial effects of weight reduction occurred in both sexes, and also in Caucasian and AfricanAmerican subjects.
14 It was concluded that weight loss was the best nonpharmacological intervention for obese-HTN.
14 For those requiring antihypertensive medications, weight loss can help to decrease the number and dosage of drugs and thereby decrease both the side effects and treatment cost.
The trial of nonpharmacological interventions in the elderly (TONE) has shown that elderly hypertensive subjects benefit from weight reduction, and have fewer cardiovascular events and HTN, compared with subjects treated with the usual care. 15 Weight loss also decreases the incidence of HTN in longitudinal studies of normotensive populations. A trial of HTN prevention, which recruited about 2400 overweight adults with high-normal BP, concluded that the incidence of HTN after 2 years was lower in those patients treated with weight loss, with reduction in salt intake or with both approaches, than in those managed with usual care only. 16 
Haemodynamic and cardiovascular changes
Decrease in BP following weight loss is associated with a rapid fall in insulin level, 17, 18 reduced SNS and RAS activity, 19, 20 and accelerated natriuresis. 21, 22 Therefore, the benefits of weight loss are likely because of the reversal of many of the haemodynamic abnormalities in obese subjects. In an earlier study, we showed that a weight loss of only 10 kg caused lower total circulating and cardiopulmonary blood volumes without changing total peripheral resistance. These changes were related to decreased venous return, cardiac output and oxygen consumption. 22 The haemodynamic changes after weight loss are associated with reduced left ventricular internal dimension during diastole, decreased septal and left ventricular systolic wall thickness. The reduction of LVH is correlated with the decrease in systolic BP, 23, 24 These haemodynamic and cardiac structural changes following weight loss significantly reduced left ventricular stroke work and led to improved cardiac function. 25 
Renal changes
Recently, Kambham et al 5 reported a 10-fold increase in the incidence of obesity-related glomerulopathy over 15 years (0.2% in 1986-1990, 2% in 1996-2000) in a large renal biopsy-based study, suggesting an emerging epidemic of obesity-glomerulopathy, which includes obesity-associated FSGS and glomerulomegaly.
In animal studies of Fisher rats with only 1/6 of their kidney left after nephrectomy 26 and in our study of uninephrectomized spontaneously hypertensive rats, 27 calorie restriction without protein restriction was found to lower urinary protein excretion and protect kidney function (GFR). A low-calorie diet also decreased the glomerular injury and mesangial expansion in the remaining kidney. Recently, we further demonstrated that in uninephrectomized spontaneously hypertensive rats, lowcalorie diets without restriction of protein could prevent renal injury by reducing glomerular growth, mesangial expansion and interstitial infiltration, 28 which supports Hall's hypothesis that obesity-HTN and nephropathy may be related to the physical compression of kidney by intrarenal fat Therapy of obesity-hypertensionaccumulation and extracellular matrix proliferation. 9 These animal data suggest that weight loss improves glomerular hyperfiltration, lessens proteinuria and renal injury, and therefore, may prevent the development of glomerular sclerosis in obesity. [26] [27] [28] In humans, obesity was reported to increase the risk for development of proteinuria and CRF after unilateral nephrectomy. 29 Weight loss by hypocaloric diet without protein restriction was shown to decrease proteinuria in obese patients with chronic proteinuric nephropathies that included diabetic nephropathy, chronic glomerulonephritis and hyperfiltration diseases. 30 More human studies are necessary to explore further the beneficial effects of weight loss on the kidney of obese patients.
Leptin change
The hormone leptin is secreted from adipocytes. After binding to the leptin receptor (Ob-R) at hypothalamus, activating multiple neuropeptide pathways, leptin decreases appetite and increases energy expenditure, and therefore, reduces adipose tissue mass and body weight. 7 Leptin also has other actions, such as activating the sympathetic system, increasing renal sodium and water excretion, improving insulin sensitivity and inhibiting glucosemediated insulin secretion. 7 A strong correlation between serum leptin level and body fat mass has been documented, which suggests a leptin-resistant mechanism in obesity. 31 Leptin resistance in obese patients may contribute to their clinical profile, such as low-energy expenditure, sodium retention, intravascular volume expansion and insulin resistance. 7 Weight loss is accompanied with a decrease in leptin levels, 32 which suggests that weight loss probably 'reverses' the leptin resistance, and improves the clinical profiles of obese subjects. Leptin was demostrated to stimulate expression of TGF-beta1 and proliferation of glomerular endothelial cells, and to increase proteinuria in rat, which suggest that leptin is a renal growth and profibrogenic factor contributing to renal injury and glomerulosclerosis. 33 
NPs changes
NPs are important regulators of volume homeostasis and arterial pressure. 7, 34 In the kidneys, NPs modulate renal vascular resistance and increase GFR; they decrease inner medullary hypertonicity and inhibit sodium reabsorption. NPs also inhibit RAS, decrease vascular resistance and BP. Several studies suggest that relative overexpression of inactive receptor (Npr-C) in adipose tissue may trap and clear more ANP from circulation and reduce its biological effects on the kidney, [34] [35] [36] which may contribute to the sodium retention in obesity.
Weight loss increases the biological activity of NPs. In rats, fasting suppressed Npr-C expression in adipose tissue accompanied with increased biological activity of atrial natriuretic peptide (ANP). 36 Obese subjects were reported to have delayed urinary sodium excretion and a blunted response of plasma ANP to saline load. 37 Weight loss induced by caloric restriction led to significant natriuresis and diuresis, together with an early increase of circulating ANP levels. 38 Dessi-Fulgheri et al 39 reported that after caloric restriction for 4 days in obese hypertensive patients, ANP infusion caused more profound diuresis, natriuresis, reduction of BP, than ANP infusion did before caloric restriction. Thus, weight loss seems to increase the biological activity of NPs that are abnormally suppressed in obesity.
In summary, weight reduction should be the first choice to treat obesity-HTN. It reverses the multiple pathogenic factors implicated in obesity-HTN. The benefits of weight loss in obese patients include (but are not limited to) improvement of insulin sensitivity, reduced SNS and RAS activities, restored leptin sensitivity, increased biological activity of NPs, accelerated natriuresis, and most importantly, decreased glomerular hyperfiltration, proteinuria and renal injury, regression of LVH and improved cardiac function.
Pharmacological treatment
The majority of obese patients find that weight reduction is difficult to maintain, and a high dropout rate in 1-2 years in weight loss program has been reported 40 When obese patients are unable to tolerate, or are unwilling to comply with weight reduction, or when weight reduction alone cannot control HTN, then antihypertensive drug therapy should be used. The ideal medications to treat HTN in obese patients would be those that specifically target to the pathogenic factors, protect the renal and cardiovascular end organs, and do not further enhance the existing metabolic abnormalities. However, there are currently no long-term studies examining the efficacy of any antihypertensive agents in reducing mortality in obese patients.
ACEI
ACEI appear to be the most appropriate drug for treating obesity-HTN. ACEI block the RAS, facilitates natriuresis and diuresis. ACEI control glomerular hyperfiltration by reversal of angiotensin-2-induced efferent arteriolar restriction, improve permselectivity, decrease proteinuria and protect kidney function. 41, 42 It has no adverse effects on lipid profiles. ACEI also improves insulin sensitivity and reduces plasma levels of insulin, norepinephrine and leptin in obese hypertensives. 33 In the first large prospective multicenter doubleblind trial performed in obese hypertensive patients Therapy of obesity-hypertension(TROPHY), 42 we studied the efficacy and safety of lisinopril compared with the hydrochlorothiazide (HCTZ). A total of 60% of patients treated with lisinopril for 3 months had diastolic BP o90 mmHg, compared with 43% of patients treated with HCTZ (Po0.05). We also found that lisinopril was more effective than HCTZ in Caucasians and young obese patients, while HCTZ was more effective in obese African-American patients. Furthermore, among those whose BP were controlled, more than half of the patients (57%) only needed low-dose lisinopril (10 mg/day), whereas 46% of patients required a high-dose HCTZ (50 mg/day) to maintain BP control. Neither treatment significantly affected insulin and lipid levels after 12 weeks, but plasma glucose increased and plasma potassium decreased significantly in patients treated with HCTZ.
In a previous small study, Reaven et al 43 noted that lisinopril was more effective than HCTZ in lowering BP in obese patients and lisinopril was not associated with adverse metabolic effects. Also, the combination of lisinopril and HCTZ could control BP in those who failed monotherapy. Another ACEI moexipril was used to treat obese postmenopausal women. It was found that moexipril was equally as effective as atenolol in reducing BP without adversely affecting lipid and carbohydrate metabolism. 44 Recently, Masuo et al 32 reported 1-year treatment of young obese hypertensives: enalapril groups (with or without weight reduction) have a greater reduction in plasma insulin, NE and particularly leptin levels than amlodipine groups (with or without weight reduction) or weight reduction alone.
Although there are currently no 'hard data' from long-term prospective studies in obese population, ACEI has been shown to have additional renal protective effects beyond the degree of BP control in patients with proteinuria, diabetic nephropathy or renal insufficiency. ACEI has been shown to decrease cardiac enlargement and preserve cardiac function in asymptomatic patients with CHF, 45 and improve both symptoms and survival in patients with overt CHF. 46, 47 . ACEI also can reduce the morbidity and mortality in patients with myocardial infarction 48 and can cause the regression of LVH. 49 As obese hypertensives are commonly associated with these renal and cardiovascular comorbid conditions (diabetes, proteinuria, renal insufficiency, LVH, CHF and coronary artery disease), they should benefit from both the renal and cardiovascular protective effects of ACEI.
ARB ARB antagonize angiotensin-2 type-1 receptor mediated biological actions, including vasoconstriction, vascular remodelling, aldosterone release and proximal sodium reabsorption. They are well tolerated and have less side effects than ACEI. ARB also improve insulin sensitivity and have no adverse effects on lipid profiles. 50 Recently, ARB irbesartan was shown to protect against the progression of type-II diabetes nephropathy (proteinuria 40.9 g/day), independent of the reduction of BP. 51 Another ARB losartan was reported to have similar renal benefits. 52 Furthermore, irbesartan was shown to have renoprotective effect on the development of diabetic nephropathy in type-II diabetic patients with microalbuminuria. 53 ARB may also provide an additive antiproteinuric effect in the combination therapy with ACEI. 54 Although there is no published trial in treating obesity-HTN, type-II diabetes and proteinuria are the common comorbid conditions in these patients, we believe that ARB could be very useful and beneficial in treating obese hypertensive patients. It provides an important alternative to the use of ACEI.
Diuretics
The hypotensive effect of thiazides is attributed initially to a reduction of intravascular and extracellular fluid volumes. Over time, this action on volume becomes less important, and the more chronic action of thiazides results chiefly from a reduction in peripheral vascular resistance.
In an early study of black obese women with HTN, we reported that chlothalidone was more effective than clonidine in reducing BP. 55 Then, in the TROPHY trial, we found that HCTZ was more effective than lisinopril in African-American obese patients in controlling HTN. 42 All the studies that have used HCTZ in obesity-HTN were short-term, and most patients required a high dose of thiazides (HCTZ, 50 mg/day) for good pressure control. 42 The prolonged use of such a high dose of thiazides will not only cause electrolyte imbalances (hypokalaemia, hypomagnesemia), but can also exacerbate some pre-existing metabolic abnormalities in obese patients, such as hyperlipidaemia, hyperglycaemia, insulin resistance and activated RAS. High doses of diuretics may be associated with an increased risk of sudden death, especially if patients have underline heart disease, or diabetes mellitus. 56, 57 However, low-dose therapy (12.5-25 mg of HCTZ or chlorthalidone) is usually safe and more cost-effective. It has been shown to decrease the incidence of stroke, AMI and coronary death in the elderly with isolated systolic HTN. 58 Diuretics also can cause moderate regression of LVH, not as much as ACEI or CCD, but more than BRB. 49 We therefore propose (Figure 1) for the pharmacological treatment of obesity-HTN, ACEI would be used first to control BP and decrease the cardiovascular and renal morbidity that characterized obesity-HTN. If just ACEI do not control BP adequately, then a diuretics in low dose is added as a second choice. Combination with a diuretics can be very helpful in patients with fluid overload or renal function Therapy of obesity-hypertensiondamage. Diuretics may also restore the antiproteinuric effect of ACEI in patients without adequate antiproteinuric response to ACEI because of the failure of dietary salt restriction. 59 CCB CCB inhibit the slow inward calcium channels, which cause relaxation of smooth muscle arterial wall and myocardial cells. CCB also induce a mild natriuresis by direct action on renal tubules. However, short-acting CCB can increase SNS and RAS activity, 60 precipitate ischaemic events and increase mortality in patients with CAD. 61 Long-acting CCB seem to be safe, and should be chosen in hypertensive patients.
Long-acting nifedipine gastrointestinal therapeutic system (GITS) was found to effectively control BP in 76% of extremely obese and 72% of moderately obese patients. The responsive rate was similar in obese and nonobese hypertensive patients. 62 Other CCB, including amlodipine, diltiazem, and nitredipine, were also found to be effective in obese patients. [63] [64] [65] CCB are considered metabolically neutral, as it does not affect insulin sensitivity or the levels of serum insulin, glucose and lipid. 8, 63, 65 CCB can reduce LVH more effectively than diuretics and BRB. 49 Nondihydropyridine CCB (diltiazem, verapamil) can also lower the heart rate, may reduce the rate of reinfarction and increase the patient survival after an AMI. 66 In the kidney, dihydropyridine CCB appear to dilate the preglomerular afferent arteriole, 67 which allows more of the systemic pressure to be translated to the glomerulus. Despite the reduction in systemic pressure by dihydropyridine CCB, the intraglomerular pressure may not be changed or even elevated. They have a variable effect on proteinuria. [67] [68] [69] Only the nondihydropyridine CCB (diltiazem, verapamil) consistently have been shown to reduce proteinuria and diabetic nephropathy progression. [69] [70] [71] These may be because of the reduction in the efferent arteriolar resistance, 67 similar to ACEI. We, therefore, propose that nondihydropyridine CCB should be used as the third choice for patients with obesity-HTN when ACEI and low-dose diuretics fail to control BP. If necessary, a dihydropyridine CCB may also be added later. It has been shown that the combination of a nondihydropyridine and a dihydropyridine CCB has additive and even synergistic effects in BP reduction. 72 
BRB
The haemodynamic and hormonal profiles of obesity-HTN, which includes activated SNS and RAS and high cardiac output, 7 may justify the use of BRB.
MacMahon et al 73 reported that metoprolol was as effective as weight reduction of 47 kg in lowering BP. Metoprolol was also reported to reduce BP more effectively in obese than in lean hypertensive patients, while CCB isradipine was more effective in controlling BP in lean than in obese hypertensive patients. 74 Another BRB atenolol was shown to be as effective as ACEI moexipril in obese postmenopausal women. 44 However, atenolol had negative effects on the glucose metabolism after 12 weeks therapy in nondiabetic obese hypertensive patients. 44 Long-term use of BRB in obese subjects may worsen their metabolic abnormalities. It increases triglycerides, decreases HDL cholesterol levels, decreases insulin sensitivity and increases insulin level. 75 BRB also interferes with a diabetic patient's awareness of hypoglycaemia. Another potential problem is that weight reduction may become difficult with BRB, which is more evident in African-American women. 76 BRB inhibits the effect of catecholamines on fatty acid metabolism, which decreases the availability of fatty acid and decreases feedback to the appetite center, and therefore leads to overeating and weight gain. 75 BRB may not reverse intraglomerular hyperfiltration and they usually have little or a lesser antiproteinuric effect. 69 BRB are also lesser effective Therapy of obesity-hypertensionthan ACE, CCB or diuretics in causing regression of LVH. 49 However, BRB were found to improve longterm survival if they were administrated following an AMI. 77 We propose that BRB may not be a good choice for uncomplicated young obese subjects. However, for those complicated with angina, CAD, CHF or arrhythmia, BRB should be considered, as its benefits may out weigh its side effects.
Centrally acting alpha-2 agonists
The most commonly used agent of this class is clonidine. It inhibits the release of norepinephrine (NE) at central ganglionic junctions, which decreases sympathetic outflow, peripheral vascular resistance and heart rate. Sustained inhibition of SNS by clonidine leads to reductions of total body sodium and plasma volume. 78 Tuck et al 60 reported that clonidine effectively lowered BP and plasma NE levels in obese hypertensive patients. In a small prospective study of obese hypertensive African-American women, we found that clonidine failed to control BP in most patients using a daily dosage of up to 0.4 mg, and that chlothalidone controlled BP more effectively than clonidine. 55 Larger studies with a higher daily dose may be necessary to evaluate its efficacy in treating obesity-HTN. Clonidine has no adverse effects on metabolic profiles. No data suggest that clonidine offer any specific renal or cardiovascular protective effects.
ARA
The hypotensive effect of ARA is because of vasodilatation by inhibiting the postsynaptic alphareceptor. It improves insulin sensitivity and induces early insulin response. ARA also decrease triglycerides and LDL cholesterol levels. 41, 79 Clinical data in obese patients are very limited.
One small study reported that prazosin significantly decreased both systolic and diastolic pressures and also increased insulin sensitivity. 80 Another small study compared ARA bunazosin with BRB atenolol in treating nondiabetic obese-HTN. Bunazosin and atenolol were equally effective in lowering BP, but bunazosin had a significantly better profile with glucose metabolism than atenolol. 81 Recently, Wofford et al 82 reported that BP in obesity is more sensitive to adrenergic blockades (combination of doxazosin and atenolol) than in lean hypertensive patients.
Our hesitation about the use of ARA in obesity-HTN comes from the conclusions of the ALLHAT study. 83 Compared with those who received clorthalidone, patients treated with doxazosin had a 25% increase in cardiovascular events and a doubling in the risk of CHF, which led to the discontinuation of the doxazosin arm in this trial. Like BRB and diuretics, ARA do not preferentially dilate the efferent arteriole, may not improve intraglomerular hypertension, and have a lesser antiproteinuric effect. 84 We propose that ARA should be used as a last-line agent for obesity-HTN except for those patients complicated with benign prostatic hypertrophy.
In summary, the challenge for a clinician to treat obesity-HTN is to select the drug or drug combinations that can specifically target the underlying pathogenesis, effectively control the HTN, not worsen existing metabolic abnormalities, and protect the targeted end organs: renal and cardiovascular systems. ACEI seem to be the most appropriate drugs. It not only can effectively lower BP, but also has favourable renal and cardiovascular protective effects and improves the metabolic abnormalities in obesity. ARB has renoprotective effects apparently similar to ACEI in type-II diabetics. It should be used as an alternative to ACEI, especially in obese diabetic patients. Thiazide diuretics seem to be particularly useful in African-American obese hypertensives, but high doses should be avoided because of its metabolic adverse effects. For many obese patients who failed the single-drug regimen, the combination of an ACEI and a low-dose thiazide diuretics may represent the 'combination of choice'. Long-acting CCB is also effective and has the advantage of no adverse metabolic effects. Nondihydropyridine CCB can provide additional renal protective effect and possible cardiovascular benefit. The major concern for using BRB in obese patients is its adverse metabolic effects and the tendency of further weight gain, though, it continues to be an important drug for those patients complicated with CAD, CHF, or arrhythmia. There is little clinical data supporting the efficacy of centrally acting alpha-2 agonists and the benefit of ARA in treating HTN in obese patients.
With consideration of both the limited clinical data on obesity-HTN and the large amount of data from essential HTN, 85 we propose the approach described in Figure 1 to treat the HTN in uncomplicated obese subjects.
